Spero Therapeutics: Funding, Investors & Team (Oct 2026)
Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.
Spero Therapeutics has raised $30.9M across 3 funding rounds on record, the most recent an undisclosed round of $9.0M announced in Nov 2022.
That round is in line with the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Spero Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2022.
Spero Therapeutics Funding Rounds
Spero Therapeutics raised $12.9M in a Grant announced in Jan 2022.
8 months later, a Post-IPO Equity of $9.0M was announced in Sep 2022.
2 months later, an undisclosed round of $9.0M was announced in Nov 2022.
Spero Therapeutics Founders and Leadership Team
Contact details for the Spero Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Spero Therapeutics Funding Compared to Other Biotechnology Startups
Spero Therapeutics' latest round of $9.0M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Spero Therapeutics in Biotechnology and Cambridge
Companies Similar to Spero Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Spero Therapeutics Funding FAQs
What does Spero Therapeutics do?
Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.
How much funding has Spero Therapeutics raised?
Spero Therapeutics has raised $30.9M across 3 rounds on record. The most recent is an undisclosed round of $9.0M announced in Nov 2022.
When did Spero Therapeutics last raise funding?
Spero Therapeutics' most recent funding round on record is an undisclosed round of $9.0M, announced in Nov 2022.
Who is the CEO of Spero Therapeutics?
Ankit Mahadevia is listed as CEO at Spero Therapeutics.
Where is Spero Therapeutics headquartered?
Spero Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Spero Therapeutics have?
Spero Therapeutics is in the 101-250 employee band.
How does Spero Therapeutics' funding compare to other Biotechnology startups?
Spero Therapeutics' latest round of $9.0M is in line with the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Spero Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Spero Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.